glp 1 patent June 2024 Highlights: GLP-1R Agonists, Polθ Inhibitors, Non-Ab PD-L1 Inhibitors, and More! Looming GLP-1 drug patent expirations

One routine to support GLP-1 and metabolic health with clinically-studied ingredients

At the time of this writing, liraglutide is the only GLP-1 RA with a labeled indication to reduce the risk of major adverse cardiovascular events (MACE), yet several other GLP-1 RAs have shown significant reduction in MACE, as summarized in Table 2

Although the reaction was of sudden onset, it did not meet the Brighton Criteria of anaphylaxis [7]

amazing product

Discussion at the American Heart Association session underscored the stakes of such decisions, as it was noted that an estimated 6.6 million American adults meet the inclusion criteria for the SELECT trial